So, in theory, pts who show low frequency mutations on gleevec could be switched to ponatinib after only three months? I don't think that's built into any ones model yet, lol.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.